La cadena de opciones muestra datos clave de las opciones de acciones de Getty Images Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Getty Images Holdings..

Getty Images Holdings (NYSE:GETY) Bolsa, Cadena de Opciones

Getty Images Holdings

Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GETY

SGMO

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

CWCO

SAIC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: SAIC, GETY, CTM, CWCO y TSQ.

5 acciones en el foco este lunes: SAIC, GETY, CTM, CWCO y TSQ

Getty Images Holdings, Inc. Class A Common Stock

Getty Images Holdings Inc

<ul>
<li>The company is expected to reduce core operational burn by 55% when compared to 2024</li>
</ul>

TCBP

TC BioPharm Announces Outsourcing Initiatives To Reduce Burn Rate And Overhead

Sjögren's disease (SjD)&nbsp;is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments&nbsp;&nbsp;
The Company is actively enrolling patients in the Phase 3 DAFFODIL study&nbsp;&nbsp;
This marks the fourth nipocalimab FDA Fast Track designation
SPRING HOUSE, Pa., March 18, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatment of adult patients with moderate-to-severe Sjögren's disease (SjD), having previously been granted <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384625-1&amp;h=3568246313&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fnipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease&amp;a=Breakthrough">Breakthrough</a>&nbsp;Therapy designation (BTD) for the investigational therapy late last year. Currently, no advanced therapies are approved to treat this disease.
Building upon the BTD, which nipocalimab is the first and only therapeutic to receive for&nbsp;SjD, the U.S. FDA's FTD is also designed to accelerate the delivery of new therapeutics to patients by facilitating the development and expediting the review of drugs that demonstrate the potential to treat serious conditions and help address unmet needs for serious or life-threatening conditions.

Biotech

General

Johnson & Johnson Announces That The U.S. FDA Has Granted Investigational Nipocalimab Fast Track Designation For The Treatment Of Adult Patients With Moderate-To-Severe Sjögren's Disease, Having Previously Been Granted Breakthrough Therapy Designation For The Investigational Therapy Late Last Year; No Advanced Therapies Are Approved To Treat This Disease

ATNM

Actinium Pharmaceuticals Announces A Clinical Trial Program For Solid Tumors Combining Actimab-A With PD-1 Checkpoint Inhibitors KEYTRUDA And OPDIVO; Clinical Proof Of Concept Data Expected In 2025

<ul>
<li>OCU200 has a very favorable safety and tolerability profile</li>
<li>No serious adverse events related to the study drug have been reported</li>
<li>Dosing of the second cohort has been approved &nbsp;</li>
</ul>
MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Phase 1 study and approved continuation of dosing in the second cohort. OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin,&nbsp;with the potential to treat diabetic macular edema (DME).

OCGN

Ocugen Announces That The Data And Safety Monitoring Board For The OCU200 Clinical Trial Recently Convened And Reviewed Safety Data Following Dosing Of The First Cohort In The Dose-Escalation Portion Of The Phase 1 Study And Approved Continuation Of Dosing In The Second Cohort

New Data Demonstrates Significant Reduction in Tumor Growth and KIT&nbsp;Expression in Preclinical GIST Models
<ul>
<li>Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours.</li>
<li>Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays.</li>
<li>Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft model, HT-KIT treatment (12.5 mg/kg IV every three days) led to a significant reduction in tumor growth, with differences becoming statistically significant by day 8 and increasing over time.</li>
<li>Consistent Tumor Size Reduction – Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements.</li>
</ul>

HOTH

Hoth Therapeutics Announces Preclinical Results For HT-KIT In Aggressive Cancer Gastrointestinal Stromal Tumors; Says HT-KIT Triggered Significant Tumor Cell Death As Early As 24 Hours Post-Treatment

Emergent BioSolutions Secures ~ $27M In International Orders To Address Potential Threats Of Smallpox And Anthrax And Will Contribute To The Overall Supply Of MCM's To The International Market In 2025

Agreement brings continued access to high-quality care for Alignment's&nbsp;Medicare Advantage members
ORANGE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Sutter Health and Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) have renewed their agreement that provides Alignment Healthcare members with continued in-network access to Sutter's integrated network of high-quality, comprehensive care in Northern California.
This agreement applies to Alignment Healthcare members enrolled in Sutter Advantage HMO and My Choice PPO health plans. The collaboration allows Sutter Health and Alignment Healthcare to further their shared vision of ensuring patients enrolled in these plans – especially critical high-risk individuals with chronic conditions – get access to care when, where and how they need it.

ALHC

Sutter Health and Alignment Healthcare Have Renewed Their Agreement That Provides Alignment Healthcare Members With Continued In-Network Access To Sutter's Integrated Network Of High-Quality, Comprehensive Care In Northern California

Hedge Funds

CVEO

Civeo 9.8% Shareholder Engine Capital Says Board Should Eliminate Dividend, 'Aggressively' Repurchase Shares, Target 1.75x Leverage Ratio And Reduce Costs To Deliver ~$47/Share For Shareholders In Standalone Scenario

Bernstein Research on Tuesday put its price target on Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) at $310, a potential 69% upside from its current price of $188.96.
The research firm highlighted <a href="https://www.benzinga.com/25/03/44194807/coinbase-analyst-sees-crypto-spring-ahead-calls-recent-pullback-a-buying-opportunity">Coinbase's dominance in the U.S. crypto market</a> and projected robust earnings growth driven by regulatory clarity and expansion of crypto trading volumes back to American shores.
What Happened: "Coinbase is uniquely positioned to capitalize on the reshoring of global crypto markets to the United States," Bernstein analysts wrote in their report.
They added that Coinbase's entrenched leadership, with over 66% U.S. market share, places it as the premier platform to benefit from an increasingly <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363340/crypto-leaders-step-up-pressure-on-sec-as-trumps-policies-reshape-regulatory-landscape">crypto-friendly regulatory environment</a>.
Bernstein expects Coinbase's earnings per share (EPS) to grow at a compound annual growth rate (CAGR) of 38% through 2026, substantially ahead of Wall Street consensus estimates. 
"We are about 30% above consensus on 2025 EPS estimates and approximately 61% ahead for 2026," the analysts noted.
The firm also pointed to the Trump administration's pro-crypto stance, including plans to make the U.S. the global hub for digital assets. 
Policies such as a stablecoin bill and digital asset market structure legislation are expected to bolster Coinbase's business. 
Bernstein emphasized that these regulatory changes should drive a return of offshore crypto volumes to U.S. markets, lifting Coinbase's revenues and offsetting competitive pressures from fintech and brokerage entrants.
Beyond trading, Bernstein praised Coinbase's growing non-trading revenue streams such as staking, stablecoin issuance and institutional custody services, which provide a buffer against the cyclicality of crypto trading volumes.
The report forecasts non-trading revenues to grow at a 31% CAGR between 2024 and 2026.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44369321/crypto-leaders-step-up-pressure-on-sec-as-trumps-policies-reshape-regulatory-landscape">Crypto Leaders Step Up Pressure On SEC As Trump&#8217;s Policies Reshape Regulatory Landscape</a>
Why It Matters: Despite looming competition from firms like Robinhood and traditional brokerages, Bernstein maintains that Coinbase's "compliance-first approach and impeccable safety track record" offer a durable advantage.
"We believe COIN trades cheap at current levels relative to its EPS growth," Bernstein wrote, noting Coinbase's price-to-earnings growth (PEG) ratio is materially lower than peers.
The firm's valuation assumes a 21x price-to-earnings multiple based on 2026 earnings, which it says is in line with fintech and broker-dealer peers.
Coinbase stock has declined roughly 24% over the past year but has rallied in tandem with improving sentiment around digital assets amid institutional adoption and regulatory tailwinds.
"The regulatory dark cloud that hovered over Coinbase has lifted," Bernstein wrote, "and this provides a fresh runway for COIN's next leg of growth."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44368336/will-bitcoin-go-up-if-donald-trump-eliminates-income-tax-for-americans-making-less-than-15">Will Bitcoin Go Up If Donald Trump Eliminates Income Tax For Americans Making Less Than $150,000?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Bernstein Targets $310 For Coinbase Stock, Cites Lifting 'Regulatory Dark Cloud'

Dividends

CTRE

CareTrust REIT Raises Quarterly Dividend From $0.29 To $0.335/Share

SCNX

SCIENTURE Announces FDA Approval Of NDA For SCN-102, Being Developed By Subsidiary Scienture, LLC

Guidance

Bitcoin Depo Q1 Revenues To Be Between $151M-$154M Vs. $133.87M Estimate, Which Would Represent Growth Of Between 9% And 11% Compared To Q1 2024

Compass Point analyst Joe Flynn initiates coverage on Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy rating and announces Price Target of $2.5.

Price Target

Initiation

Analyst Ratings

Compass Point Initiates Coverage On Canaan with Buy Rating, Announces Price Target of $2.5

<h3>Gainers</h3>
<ul>
<li>Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) stock moved upwards by 22.2% to $12.0 during Tuesday's pre-market session. The company's market cap stands at $1.0 billion. </li>
<li>Heidmar Maritime Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) stock rose 12.22% to $3.03. The market value of their outstanding shares is at $173.0 million. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) shares moved upwards by 10.74% to $22.57. The market value of their outstanding shares is at $32.5 million. </li>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) shares increased by 10.0% to $1.1. The market value of their outstanding shares is at $122.2 million. </li>
<li>Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) shares moved upwards by 7.69% to $3.78. The company's market cap stands at $293.3 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) stock increased by 7.41% to $0.18. The company's market cap stands at $5.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) shares decreased by 7.6% to $5.11 during Tuesday's pre-market session. The company's market cap stands at $326.2 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 7.08% to $0.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) stock declined by 6.45% to $8.71. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Aureus Greenway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock fell 5.3% to $0.53. The market value of their outstanding shares is at $7.3 million. </li>
<li>Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) stock decreased by 4.78% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock fell 4.52% to $0.56. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACEL

ARHS

FLWS

LGCB

LITB

NVFY

YOSH

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 58.9% to $29.39 during Tuesday's pre-market session. The company's market cap stands at $382.4 million. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock increased by 52.68% to $0.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock increased by 20.06% to $28.0. The company's market cap stands at $997.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares increased by 18.37% to $0.56. The company's market cap stands at $29.0 million. The company's, Q2 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 17.46% to $0.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 16.07% to $0.68. The company's market cap stands at $48.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 35.9% to $0.55 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares decreased by 26.26% to $0.94. The company's market cap stands at $73.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 22.79% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 21.56% to $79.5. The market value of their outstanding shares is at $7.5 billion. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock decreased by 18.55% to $2.02. The company's market cap stands at $17.3 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock fell 17.69% to $2.7. The company's market cap stands at $365.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

BIAF

CTOR

HROW

HYPR

INNV

SRPT

SYRS

VRPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) shares increased by 22.1% to $1.49 during Tuesday's pre-market session. The market value of their outstanding shares is at $41.7 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares moved upwards by 16.99% to $0.69. The company's market cap stands at $54.8 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock increased by 13.18% to $3.16. The company's market cap stands at $6.1 million. </li>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) stock increased by 9.18% to $4.4. The company's market cap stands at $149.0 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock rose 8.68% to $3.75. The market value of their outstanding shares is at $57.2 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares rose 8.1% to $0.32. The market value of their outstanding shares is at $14.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) shares decreased by 16.1% to $28.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $197.7 million. </li>
<li>Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) stock declined by 13.49% to $0.53. The market value of their outstanding shares is at $77.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock decreased by 11.98% to $0.4. </li>
<li>Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) stock fell 11.41% to $1.01. The market value of their outstanding shares is at $153.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>SKK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) stock decreased by 9.27% to $0.8. The company's market cap stands at $12.5 million. </li>
<li>Techprecision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPCS#NASDAQ">TPCS</a>) shares fell 7.7% to $2.4. The company's market cap stands at $23.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESEA

IPDN

LASE

LGCL

MCRP

NRGV

OPTT

PITA

RAYA

SUNE

TPCS

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares increased by 10.3% to $71.5 during Tuesday's pre-market session. The company's market cap stands at $1.6 billion. </li>
<li>Verb Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares increased by 9.35% to $6.08. The market value of their outstanding shares is at $6.0 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares rose 8.13% to $3.59. The company's market cap stands at $4.1 million. </li>
<li>CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) stock rose 6.83% to $1.25. The company's market cap stands at $32.0 million. </li>
<li>Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) stock moved upwards by 6.58% to $3.4. The company's market cap stands at $203.9 million. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) stock rose 6.35% to $0.29. The market value of their outstanding shares is at $11.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) stock declined by 11.1% to $4.65 during Tuesday's pre-market session. The company's market cap stands at $50.7 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares declined by 9.85% to $10.08. The company's market cap stands at $2.6 billion. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares decreased by 9.75% to $1.39. The company's market cap stands at $24.3 million. </li>
<li>Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) stock declined by 9.03% to $19.55. The company's market cap stands at $114.0 million. </li>
<li>BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) stock decreased by 7.45% to $3.23. The company's market cap stands at $920.1 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares decreased by 6.42% to $0.8. The company's market cap stands at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUID

BBAI

CLPS

DGNX

INTZ

NVNI

OBLG

QBTS

QMCO

VERB

ZEPP

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study.
Presentation details:
Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in Subjects not at Risk for Influenza Complications

CDTX

Cidara Therapeutics Announces 2 Presentations On CD388 In Influenza At ICAR 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects

ALZN

Alzamend Neuro Plans Initiation Date Of Phase II Clinical Trial Of AL001 For Major Depressive Disorder

Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) reported quarterly sales of $136.827 million which beat the analyst consensus estimate of $131.497 million by 4.05 percent. This is a 7.80 percent decrease over sales of $148.406 million the same period last year.

Earnings Beats

Bitcoin Depot Q4 Sales $136.827M Beat $131.497M Estimate

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of Shareholders

Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, DFS, GETY on Behalf of Shareholders

Getty Images and Verizon to Award $20,000 Grant to Champion Disability Representation in the Workplace

Financing

Getty Images Holdings, Inc. Announces Comprehensive Refinancing of Approximately $1.042 Billion Existing Term Loans

Getty Images to Release Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Sports

Getty Images and UEFA Renew Multi-Year Agreement

Getty Images Signs Multi-Year Photography Partnership with the National Women's Soccer League

Getty Images Reports Fourth Quarter and Full Year 2024 Results

CLBR

NARI

NEUE

TURN

VINC

Angi

Bumble

Cars.com

Trump Media & Technology Group Corp. - Warrants

Trump Media & Technology

EverQuote

FuboTV

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

Outbrain

QuinStreet

Shutterstock

Taboola.com

Tripadvisor

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Vimeo

Vtex

WEBTOON Entertainment Inc. - Common stock

Webtoon Entertainment

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Yelp

Ziff Davis

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

Getty Images Holdings

Getty Images Holdings (GETY) Opciones

Getty Images Holdings (NYSE:GETY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL